The compound patent provides protection for Alimta in the US through January of 2017.
Lilly senior vice president and general counsel Robert Armitage said the company is delighted with ruling from the Court of Appeals affirming the validity of the compound patent for Alimta.
"By affirming the district court ruling, we believe that the Court fairly applied long-standing patent law principles," Armitage added.
"Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the physicians and patients we serve, as these rights help support the development of the next generation of innovative medicines to treat unmet medical needs."